Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

  • Revenue in CHF (TTM)62.80bn
  • Net income in CHF13.93bn
  • Incorporated1966
  • Employees100.92k
  • Location
    Roche Holding AGGrenzacherstr. 124BASEL 4058SwitzerlandCHE
  • Phone+41 9 732354295
  • Websitehttp://www.roche.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bayer AG47.66bn2.26bn64.37bn100.75k28.451.6711.881.352.242.2447.2238.110.37981.623.37465,610.201.82-1.372.42-1.7762.7259.994.80-3.730.88267.250.5308--6.484.76106.42-23.200.2547-5.52
Novartis AG50.96bn23.25bn211.38bn110.00k8.523.297.254.1510.3210.3222.6726.740.42922.196.36488,450.4019.589.0825.8911.5671.0270.6245.6224.731.01--0.336458.805.971.38197.5829.050.63113.44
Roche Holding AG62.80bn13.93bn274.63bn100.92k20.5710.8814.174.3716.1916.1973.0230.600.70382.605.99622,285.0016.7415.6227.8223.7769.1971.0423.7821.820.726627.460.52462.047.684.42-2.557.78-1.992.55
Data as of May 25 2022. Currency figures normalised to Roche Holding AG's reporting currency: Swiss Franc CHF

Institutional shareholders

14.83%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 05 May 202219.39m2.76%
Norges Bank Investment Managementas of 31 Dec 202118.01m2.56%
BlackRock Fund Advisorsas of 04 May 202211.99m1.71%
UBS Asset Management Switzerland AGas of 03 May 202211.75m1.67%
Fidelity Management & Research Co. LLCas of 31 Mar 202211.12m1.58%
Credit Suisse Asset Management (Schweiz) AGas of 29 Apr 20229.03m1.29%
Z�rcher Kantonalbank (Investment Management)as of 31 Jan 20226.83m0.97%
BlackRock Advisors (UK) Ltd.as of 04 May 20225.79m0.82%
Massachusetts Financial Services Co.as of 30 Apr 20225.20m0.74%
Alecta Pension Insurance Mutualas of 31 Dec 20195.09m0.73%
More ▼
Data from 31 Dec 2021 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.